Change of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B

Change of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B - Change of HBsAg during long-term NA therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007993

Enrollment

700

Registered

2012-05-21

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronically HBV infected patients receiving NA therapy (lamivudine, adefovir, entecavir) for more than 6 month.

Exclusion criteria

Exclusion criteria: HCV co-infection HIV co-infection

Design outcomes

Primary

Measure	Time frame
HBsAg clearance	—

Countries

Japan

Outcome results